The prevalence of Mycoplasma genitalium (MG) and Trichomonas vaginalis (TV) at testing centers in Belgium, Germany, Spain, and the UK using the cobas TV/MG molecular assay

Perry, M. D.; Jones, Sophie; Bertram, Alexander; Salazar, Adolfo de; Barrientos‐Durán, Antonio; Schiettekatte, Gilberte; Lewinski, Michael A.; Arcenas, Rodney; Hansra, Avneet; Njoya, Merlin; García, Féderico

doi:10.1007/s10096-022-04521-5

Cited by 9 publications

(7 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, lower positivity ratios were found in samples from laboratories testing MG in all samples collected for STI screening (0.8 to 5.0%). These estimates may reflect the actual prevalence of MG in the population and are consistent with estimates from other European countries [21,22].…”

Section: Discussionsupporting

confidence: 84%

Estimation of antimicrobial resistance of Mycoplasma genitalium, Belgium, 2022

De Baetselier,

Smet,

Kehoe

et al. 2024

Eurosurveillance

Self Cite

View full text Add to dashboard Cite

Background Antimicrobial resistance (AMR) of Mycoplasma genitalium (MG) is a growing concern worldwide and surveillance is needed. In Belgium, samples are sent to the National Reference Centre of Sexually Transmitted Infections (NRC-STI) on a voluntary basis and representative or robust national AMR data are lacking. Aim We aimed to estimate the occurrence of resistant MG in Belgium. Methods Between July and November 2022, frozen remnants of MG-positive samples from 21 Belgian laboratories were analysed at the NRC-STI. Macrolide and fluoroquinolone resistance-associated mutations (RAMs) were assessed using Sanger sequencing of the 23SrRNA and parC gene. Differences in resistance patterns were correlated with surveillance methodology, socio-demographic and behavioural variables via Fisher’s exact test and logistic regression analysis. Results Of the 244 MG-positive samples received, 232 could be sequenced for macrolide and fluoroquinolone RAMs. Over half of the sequenced samples (55.2%) were resistant to macrolides. All sequenced samples from men who have sex with men (MSM) (24/24) were macrolide-resistant. Fluoroquinolone RAMs were found in 25.9% of the samples and occurrence did not differ between socio-demographic and sexual behaviour characteristics. Conclusion Although limited in sample size, our data suggest no additional benefit of testing MG retrieved from MSM for macrolide resistance in Belgium, when making treatment decisions. The lower occurrence of macrolide resistance in other population groups, combined with emergence of fluoroquinolone RAMs support macrolide-resistance testing in these groups. Continued surveillance of resistance in MG in different population groups will be crucial to confirm our findings and to guide national testing and treatment strategies.

show abstract

Section: Discussionsupporting

confidence: 84%

Estimation of antimicrobial resistance of Mycoplasma genitalium, Belgium, 2022

De Baetselier,

Smet,

Kehoe

et al. 2024

Eurosurveillance

Self Cite

View full text Add to dashboard Cite

show abstract

“…In young high-risk women with asymptomatic bacterial vaginosis in the United States, the prevalence of M. genitalium co-infection with C. trachomatis was 29.9%, and co-infection with Neisseria gonorrhoeae was 23.6% [ 14 ]. However, in a study conducted in Belgium, Germany, Spain, and the United Kingdom, the co-infection rate of M. genitalium with C. trachomatis was only 0.6%, and with N. gonorrhoeae was 0.1% [ 15 ]. In our study, co-infection of C. trachomatis and M. genitalium was not observed, likely due to differences in the study population and the low positive rates of C. trachomatis and M. genitalium .…”

Section: Discussionmentioning

confidence: 99%

Association between co-infection with Chlamydia trachomatis or Mycoplasma genitalium and cervical lesions in HPV-positive population in Hunan, China: a cross-sectional study

Jiang,

Ding,

et al. 2023

Infect Agents Cancer

View full text Add to dashboard Cite

Objectives The aim of this study was to determine the prevalence of Chlamydia trachomatis (CT) and Mycoplasma genitalium (MG) among HPV-positive women undergoing colposcopy at the Second Xiangya Hospital of Central South University, Hunan, China. Additionally, we aimed to assess the impact of C. trachomatis or M. genitalium co-infection with HPV on the severity of cervical lesions. Methods We collected HPV data, cervical cytology results, and demographic information from 439 women attending colposcopy. Cervical swabs were obtained for simultaneous amplification testing (SAT) of C. trachomatis and M. genitalium. Multivariate logistic regression analyses were performed to examine the association between sexually transmitted pathogens and cervical lesions. Results Among the participants, C. trachomatis was detected in 17 (3.87%) individuals, and M. genitalium in 16 (3.64%) individuals. There was no co-infection of C. trachomatis and M. genitalium. The highest prevalence of M. genitalium was observed in women aged 19–30 years (10.20%; 95% CI, 1.41-18.99%), with a subsequent decline in prevalence with increasing age (Ptrend = 0.014). The most common HPV subtype in our study was HPV52 (30.79%), followed by HPV16 (18.62%), HPV58 (16.95%), and HPV53 (10.02%). Infection with HPV16 (OR = 3.43, 95% CI, 2.13–5.53), HPV31 (OR = 3.70, 95% CI, 1.44–9.50), and HPV33 (OR = 3.71, 95% CI, 1.43–9.67) was associated with an increased severity of cervical lesions, while HPV53 infection was not likely to lead to advanced cervical lesions (OR = 0.45, 95% CI, 0.23–0.89). The leukocyte level in vaginal secretions (P = 0.042) and cervical cytology results (P < 0.001) showed associations with the degree of cervical lesions. However, there was no significant association between C. trachomatis or M. genitalium infection and the severity of cervical lesions, nor with their co-infection with HPV16. Conclusions There was no correlation between co-infection of Chlamydia trachomatis or Mycoplasma genitalium and the degree of cervical lesions in HPV-positive population in Hunan, China. Our findings emphasized the need to pay more attention to M. genitalium infection among young women. Increased levels of leukocytes in vaginal secretions may be linked to cervical lesions. HPV16, HPV31, and HPV33 in Hunan province, China, may exhibit higher cervical pathogenicity.

show abstract

“…Nevertheless, the number of reports about trichomoniasis prevalence in Europe are scarce; the last global estimation reported an increase in prevalence from 1.0% in data collected by the WHO from 2005–2012 to 1.6% between 2009–2016 in women, while in men it doubled [ 2 , 3 ]. In Spain, in particular, only four prevalence studies have been carried out, three of them in Granada (2011–2014) [ 4 , 5 , 6 ] and one in the Community of Madrid with clinical data from 2013–2017 [ 7 ], showing that in this country, the prevalence of trichomoniasis might be between 0.8–2.4%. However, the real prevalence in Spain is unknown, and further studies are necessary.…”

Section: Introductionmentioning

confidence: 99%

Impact of COVID-19 Pandemic on the Trends of Trichomonas vaginalis Infection in a Tertiary Hospital of Madrid, Spain

Bolumburu,

Zamora,

Muñoz-Algarra

et al. 2024

Microorganisms

View full text Add to dashboard Cite

More than one million sexually transmitted infections (STIs) occur every day, and Trichomonas vaginalis is responsible for more than 156 million cases each year worldwide. Nevertheless, epidemiological studies of this parasite in Europe are scarce. The aim of this study was to evaluate the impact that the COVID-19 pandemic may have had in the diagnosis and epidemiology of trichomoniasis. All available data from January 2018 to December 2021 for T. vaginalis isolation on gynecologic patients attending a Spanish Tertiary Hospital were analyzed. Pre-pandemic results (2018–2019) were compared to pandemic results (2020–2021). The pre-pandemic T. vaginalis prevalence in women was 1.15% (95% Confidence Interval, CI: 0.94–1.41), and significantly decreased in 2020–2021 (0.77%, 95% CI: 0.57–1.03; p = 0.025). Demographic nor clinical characteristics of women diagnosed with trichomoniasis did not statistically differ between the periods, although an increase in chlamydia co-infected patients was observed in the latest (from 8% in 2018–2019 to 19% in 2020–2021). This study has detected a decrease in the diagnosis of trichomoniasis; however, this is probably due to the increase in the healthcare pressure triggered by the pandemic. More than 75% of the cases diagnosed in 2021 occurred in the second half, which suggests that special attention should be given to the evolution in the coming years once normality has been restored in hospitals. Moreover, these results warn of the lack of routine diagnosis of trichomoniasis during pregnancy and the absence of specific protocols for possible co-infections, which could become a strategy to reduce the growing trend of STIs, including T. vaginalis detection, as an interesting marker of sexual risk behaviors.

show abstract

The prevalence of Mycoplasma genitalium (MG) and Trichomonas vaginalis (TV) at testing centers in Belgium, Germany, Spain, and the UK using the cobas TV/MG molecular assay

Cited by 9 publications

References 36 publications

Estimation of antimicrobial resistance of Mycoplasma genitalium, Belgium, 2022

Estimation of antimicrobial resistance of Mycoplasma genitalium, Belgium, 2022

Association between co-infection with Chlamydia trachomatis or Mycoplasma genitalium and cervical lesions in HPV-positive population in Hunan, China: a cross-sectional study

Impact of COVID-19 Pandemic on the Trends of Trichomonas vaginalis Infection in a Tertiary Hospital of Madrid, Spain

Contact Info

Product

Resources

About